Kuano Ltd

Based in the UK, Kuano Ltd leverages quantum computing and artificial intelligence to innovate drug discovery processes, enhancing the design and optimization of pharmaceutical compounds. Founded in 2020, Kuano Ltd, headquartered in Cambridge, UK, focuses on advancing drug discovery through quantum computing. The company was co-founded by David Wright, Jarryl Doyley, and Vid Stojevic, who currently serves as CEO. Kuano has completed 2 funding deals, with the most recent being a Seed round on December 21, 2022, raising GBP 1.

334 million led by Mercia Asset Management and involving other investors such as ACF Investors and Ascension Ventures. The total amount raised by the company is GBP 1. 334 million, with a current valuation of GBP 7 million. Kuano specializes in revolutionizing drug discovery through the integration of quantum computing and artificial intelligence (AI).

The company's primary offerings include advanced computational platforms that facilitate the design and optimization of pharmaceutical compounds at a molecular level. These platforms utilize quantum simulations to predict the interactions and efficacy of drug candidates, streamlining the research and development process for pharmaceutical companies. Kuano targets a diverse client base, including biopharmaceutical companies, research institutions, and academic organizations across North America, Europe, and Asia, aiming to address critical challenges in drug discovery. Kuano generates revenue through a combination of subscription models and partnerships with research institutions and pharmaceutical companies.

Their business transactions typically involve licensing quantum-enabled drug discovery software to clients on an annual subscription basis, facilitating continuous access to updates and new features. Additionally, Kuano engages in collaborative research agreements, where clients pay for bespoke services and insights from their quantum simulations, with pricing based on tiered packages tailored to specific needs. Notable offerings include their flagship quantum computing platform, which supports applications in medicinal chemistry and drug design. In December 2022, Kuano Ltd.

raised GBP 1. 33 million in Seed funding to support its laboratory work, management team, and overall growth, valuing the company at GBP 7 million post-money. The funding will enable Kuano to enhance its current offerings and potentially develop new products aimed at the pharmaceutical sector. The company plans to explore expansion into new geographic markets, including North America and Asia, to increase its client base and broaden the reach of its innovative technologies.